MacroGenics flips over an OS dud for cancer drug Margenza in surprising turnaround from earlier data

Cancer player MacroGenics scored a big win with its full approval for anti-HER2 drug Margenza last winter based on a head-to-head matchup with breast cancer titan Herceptin. Now, a fuller look at Margenza’s survival data months after that approval could spell a rough road ahead for the drug.